Surmodics Reports Decline in Revenue and Increasing Losses Amid Merger Talks with BCE Parent LLC

Company Overview: Surmodics, Inc. (NASDAQ: SRDX) specializes in medical device coating technologies and in vitro diagnostic components. The company focuses on vascular intervention products and has recently been involved in a merger agreement potentially worth $43.00 per share with BCE Parent LLC.

Income Statement Highlights:

• Total Revenue: $28.1 million for Q2 2025, a decline of 12% from $31.9 million in Q2 2024.
• Operating Loss: $(4.0) million in Q2 2025, compared to a profit of $0.7 million in Q2 2024.
• Net Loss: $(5.2) million in Q2 2025, versus a profit of $0.2 million in Q2 2024.
• Basic Net Loss per Share: $(0.36) in Q2 2025, down from $0.02 in Q2 2024.
• Operating Expenses: Increased SG&A expenses by 15% to $15.0 million in Q2 2025 due to merger-related costs.
• R&D Expenses: Decreased 18% to $8.4 million in Q2 2025 from $10.2 million in Q2 2024.
• Product Sales in Medical Device Segment: $7.7 million, down 31% year-over-year.
• Royalties and License Fees: Down 7% to $9.6 million in Q2 2025.

Positives:

• Increased revenue from Research and Development activities, reflecting growth in performance coating services.
• Successful commercialization and approval of SurVeil drug-coated balloons enhancing product portfolio.

Negatives:

• Overall revenue decline due to reduced demand and sales, particularly for the SurVeil DCB.
• Operating loss significantly increased due to merger-related charges and declining product gross margins.
• Cash and equivalents fell to $29.2 million, a drop from previous periods, stressing liquidity concerns.

Cash Flow Summary:

• Cash Used in Operating Activities: $(6.9) million for six months ended March 31, 2025.
• Net Change in Cash: $(6.9) million decrease since prior period.

Outlook:

• Anticipation of continued revenue decline primarily from SurVeil DCB products.
• Merger with BCE Parent LLC is subject to regulatory approval and may face legal challenges from the FTC, which could impact future earnings and operational stability.

For more detailed financial insights, visit the official SEC filing for Surmodics, Inc..